CCCC

C4 Therapeutics Inc (CCCC) | Rumor.io

C4 Therapeutics

CCCC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,258

Bullish sentiment (50-day avg)94%

Price to earnings ratio-2.46

Market capitalization383.2M

Earnings per share-0.91

Dividend yield (TTM)—

Revenue (annual)35.9M

Net income (annual)-105M

Social

What share of all stock conversation is about CCCC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 8

The company's stock price has increased, with some users buying in at $3.8/share and others at $3.80, with one user stating they now have a full position.
One user mentions a possible opportunity due to a fund's rebalancing in the second half of the year, which may have contributed to the stock's round tripping.
The stock has been in a downtrend since July 1st, but some users are buying in on dips, with one user stating they added to their position on weakness.

Generated by AI

Sentiment

Of the messages about CCCC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	97.06% -2.94	98.89% +20.32	73.36% -6.93
Bearish	0%	2.94% new	1.11% -20.32	26.64% +6.93

Bullish· May 13

C4 Therapeutics, Inc. (CCCC) is showing quiet strength as biotech sentiment improves, with the stock trading around $3.10-$3.17 and intraday highs reaching $3.95.
The chart for C4 Therapeutics, Inc. (CCCC) is starting to look healthier, with a possible triple top breakout and the daily Bollinger Band about to blow, indicating a potential price increase.
C4 Therapeutics, Inc. (CCCC) is on track to hit $6.62 this year, according to a prediction made last March, and may also reach $5, $7, or $10 in the near future.

Bearish· May 13

The asset's price may not be sustainable, as it has previously experienced a similar spike in March, only to drop below $2.80 after a day.
The asset's recent performance may be a sign of a triple top breakout, which could indicate a reversal in the market trend.
The asset's price may be facing significant resistance at $4.27, with a large number of shares available for sale, which could put downward pressure on the price.

Generated by AI

Topics

Of the messages about CCCC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	71.43%	92.12%	62.87%
Technical Analysis	100%	28.57%	2.42%	32.42%
Earnings	0%	0%	0%	0.47%
Macro	0%	0%	5.45%	2.26%
Analysts	0%	0%	0%	1.7%
Controversies	0%	0%	0%	0.28%

Analysts· Dec 13

C4 Therapeutics, Inc. (CCCC) was upgraded to Buy by Stifel Nicolaus with a price target raised to $12 from $2.
Multiple analysts, including Bradley Canino from Stifel, Etzer Darout from BMO Capital, and Christopher Liu from Leerink Partners, cover CCCC and have price targets of $12, $16, and $14, respectively.
CCCC's shares gained 71% to $3.99 after the company announced positive data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma, leading to upgrades and increased price targets.

Announcements· Apr 9

C4 Therapeutics, Inc. (CCCC) has expanded its long-term partnership with Roche through a new collaboration agreement focused on discovering and developing degrader-antibody conjugates (DACs) for oncology targets.
The deal includes a $20 million upfront payment, potential milestone payments of over $1 billion, and tiered royalties on future sales, with Roche leading testing and commercial launch.
The partnership aims to develop DACs that can break down harmful proteins linked to cancer, targeting hard-to-treat tumors, and builds on the companies' existing partnership that began in 2016.

Controversies· Nov 13

CCCC's subsidiary, John Holland, is a major construction company in Australia, raising concerns about potential government influence.
The company's Chinese ownership may pose risks to national security and infrastructure projects.
Critics are questioning the implications of CCCC's significant presence in Australia's construction industry.

Macro· Nov 13

CCCC's Australian subsidiary, John Holland, is involved in large public infrastructure projects, raising concerns about potential risks.
The company's foreign ownership and influence on Australian infrastructure may have implications for the country's economy and security.
This situation highlights the complex relationships between international corporations and national interests in the construction and infrastructure sectors.

Technical Analysis· Mar 9

$CCCC is up 23% and may hit 50% gain, with current price at $3.74.
Price is holding near highs, indicating a potential breakout leg.
The stock is stabilizing with steady bids underneath, and may reclaim the recent breakdown area, flipping sentiment.

Generated by AI

Community

Of the messages about CCCC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	31.91%	35.9%	55.89%	48.84%
Newcomers	68.09%	64.1%	44.11%	51.16%

Regulars· Sep 15

C4 Therapeutics, Inc. stock has seen a significant surge in price, with the stock up almost $2.00 and options up 160%.
The company has received upgrades from Stephens, including an upgrade to Overweight from Equalweight, and a raised target price to $6 from $3.
The regulars are focusing on the stock's potential for a squeeze, citing the locked-up float and the potential for a significant move.

Newcomers· Apr 9

C4 Therapeutics, Inc. ($CCCC) expands its partnership with Roche through a new collaboration agreement focused on discovering and developing degrader-antibody conjugates, with a potential $1B in milestones.
The partnership is expected to have a positive impact on the company's stock, with some users initiating or increasing their positions in anticipation of the collaboration's success.
The collaboration aims to further research into the innovative degrader-antibody conjugate modality, which could lead to emerging cancer treatment developments, with the stock up 5% in pre-market trading.

Generated by AI

News

C4 Therapeutics presents cemsidomide trial biomarker data

5d agoInvesting.com

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.

6d agoYahoo Finance

C4 Therapeutics at Wells Fargo conference: cemsidomide takes center stage

19d agoInvesting.com

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts (NASDAQ:CCCC)

25d agoSeeking Alpha

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1mo agoYahoo Finance

Wells Fargo Releases a Buy Rating on C4 Therapeutics (CCCC)

Detailed price information for C4 Therapeutics Inc (CCCC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about CCCC also mention

#	Name	Attention
1	Shattuck Labs, Inc.STTK	0%new
2	Kymera Therapeutics Inc.KYMR	0%0
3	Arvinas, Inc.ARVN	0%+0
4	Arcutis Biotherapeutics, Inc.ARQT	0%+0
5	PBLA - Panbela Therapeutics, Inc.	——
6	Sera Prognostics, Inc. Class A Common StockSERA	0%0
7	Bicycle Therapeutics plc - ADRBCYC	0%0
8	IDEAYA Biosciences Inc.IDYA	0%-0.01
9	OMGA - Omega Therapeutics, Inc.	——
10	MINM - Minim, Inc.	——

C4 Therapeutics Inc

Healthcare
Biotechnology

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity. The company develops small-molecule medicines built on its proprietary TORPEDO platform, which is used to design and optimize degraders for difficult-to-treat diseases. Its current pipeline is centered on oncology, with programs aimed at cancers such as multiple myeloma, lymphoma, melanoma, colorectal cancer, and non-small cell lung cancer. C4 Therapeutics also works through strategic collaborations with other biopharmaceutical companies to expand the reach of its technology and advance new therapeutic candidates. Based in Watertown, Massachusetts, C4 Therapeutics plays a specialized role in the biotechnology market by advancing a next-generation therapeutic modality that seeks to address targets and pathways not readily handled by traditional small-molecule drugs.

Website

Location

490 Arsenal Way

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about CCCC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Jul 8

The company's stock price has increased, with some users buying in at $3.8/share and others at $3.80, with one user stating they now have a full position.
One user mentions a possible opportunity due to a fund's rebalancing in the second half of the year, which may have contributed to the stock's round tripping.
The stock has been in a downtrend since July 1st, but some users are buying in on dips, with one user stating they added to their position on weakness.

Generated by AI

Sentiment

Of the messages about CCCC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	97.06% -2.94	98.89% +20.32	73.36% -6.93
Bearish	0%	2.94% new	1.11% -20.32	26.64% +6.93

Bullish· May 13

C4 Therapeutics, Inc. (CCCC) is showing quiet strength as biotech sentiment improves, with the stock trading around $3.10-$3.17 and intraday highs reaching $3.95.
The chart for C4 Therapeutics, Inc. (CCCC) is starting to look healthier, with a possible triple top breakout and the daily Bollinger Band about to blow, indicating a potential price increase.
C4 Therapeutics, Inc. (CCCC) is on track to hit $6.62 this year, according to a prediction made last March, and may also reach $5, $7, or $10 in the near future.

Bearish· May 13

The asset's price may not be sustainable, as it has previously experienced a similar spike in March, only to drop below $2.80 after a day.
The asset's recent performance may be a sign of a triple top breakout, which could indicate a reversal in the market trend.
The asset's price may be facing significant resistance at $4.27, with a large number of shares available for sale, which could put downward pressure on the price.

Generated by AI

Topics

Of the messages about CCCC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	71.43%	92.12%	62.87%
Technical Analysis	100%	28.57%	2.42%	32.42%
Earnings	0%	0%	0%	0.47%
Macro	0%	0%	5.45%	2.26%
Analysts	0%	0%	0%	1.7%
Controversies	0%	0%	0%	0.28%

Analysts· Dec 13

C4 Therapeutics, Inc. (CCCC) was upgraded to Buy by Stifel Nicolaus with a price target raised to $12 from $2.
Multiple analysts, including Bradley Canino from Stifel, Etzer Darout from BMO Capital, and Christopher Liu from Leerink Partners, cover CCCC and have price targets of $12, $16, and $14, respectively.
CCCC's shares gained 71% to $3.99 after the company announced positive data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma, leading to upgrades and increased price targets.

Announcements· Apr 9

C4 Therapeutics, Inc. (CCCC) has expanded its long-term partnership with Roche through a new collaboration agreement focused on discovering and developing degrader-antibody conjugates (DACs) for oncology targets.
The deal includes a $20 million upfront payment, potential milestone payments of over $1 billion, and tiered royalties on future sales, with Roche leading testing and commercial launch.
The partnership aims to develop DACs that can break down harmful proteins linked to cancer, targeting hard-to-treat tumors, and builds on the companies' existing partnership that began in 2016.

Controversies· Nov 13

CCCC's subsidiary, John Holland, is a major construction company in Australia, raising concerns about potential government influence.
The company's Chinese ownership may pose risks to national security and infrastructure projects.
Critics are questioning the implications of CCCC's significant presence in Australia's construction industry.

Macro· Nov 13

CCCC's Australian subsidiary, John Holland, is involved in large public infrastructure projects, raising concerns about potential risks.
The company's foreign ownership and influence on Australian infrastructure may have implications for the country's economy and security.
This situation highlights the complex relationships between international corporations and national interests in the construction and infrastructure sectors.

Technical Analysis· Mar 9

$CCCC is up 23% and may hit 50% gain, with current price at $3.74.
Price is holding near highs, indicating a potential breakout leg.
The stock is stabilizing with steady bids underneath, and may reclaim the recent breakdown area, flipping sentiment.

Generated by AI

Community

Of the messages about CCCC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	31.91%	35.9%	55.89%	48.84%
Newcomers	68.09%	64.1%	44.11%	51.16%

Regulars· Sep 15

C4 Therapeutics, Inc. stock has seen a significant surge in price, with the stock up almost $2.00 and options up 160%.
The company has received upgrades from Stephens, including an upgrade to Overweight from Equalweight, and a raised target price to $6 from $3.
The regulars are focusing on the stock's potential for a squeeze, citing the locked-up float and the potential for a significant move.

Newcomers· Apr 9

C4 Therapeutics, Inc. ($CCCC) expands its partnership with Roche through a new collaboration agreement focused on discovering and developing degrader-antibody conjugates, with a potential $1B in milestones.
The partnership is expected to have a positive impact on the company's stock, with some users initiating or increasing their positions in anticipation of the collaboration's success.
The collaboration aims to further research into the innovative degrader-antibody conjugate modality, which could lead to emerging cancer treatment developments, with the stock up 5% in pre-market trading.

Generated by AI

C4 Therapeutics

Social

Jul 8

Bullish· May 13

Bearish· May 13

Analysts· Dec 13

Announcements· Apr 9

Controversies· Nov 13

Macro· Nov 13

Technical Analysis· Mar 9

Regulars· Sep 15

Newcomers· Apr 9

C4 Therapeutics presents cemsidomide trial biomarker data

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics at Wells Fargo conference: cemsidomide takes center stage

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts (NASDAQ:CCCC)

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Wells Fargo Releases a Buy Rating on C4 Therapeutics (CCCC)

Also Discussed

C4 Therapeutics Inc

Company Information

Location

C4 Therapeutics presents cemsidomide trial biomarker data

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics at Wells Fargo conference: cemsidomide takes center stage

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts (NASDAQ:CCCC)

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Wells Fargo Releases a Buy Rating on C4 Therapeutics (CCCC)

Also Discussed

Social

Jul 8

Bullish· May 13

Bearish· May 13

Analysts· Dec 13

Announcements· Apr 9

Controversies· Nov 13

Macro· Nov 13

Technical Analysis· Mar 9

Regulars· Sep 15

Newcomers· Apr 9